Skip to main content

Table 4 Comparison between survivors and non-survivors in COVID-19 patients with cancer

From: Clinical features and death risk factors in COVID-19 patients with cancer: a retrospective study

Clinical features All patients (n = 103) Survivor (n = 91) Non-survivor (n = 12) P-value
Age 66.0 (24.0–90.0) 66 (24.0–90.0) 66 (56.0–81.0) 0.487
Gender     0.061
 Female 47 (45.6%) 45 (44.6%) 2 (16.7%)  
 Male 56 (54.4%) 56 (55.4%) 10 (83.3%)  
Smoking 20 (19.4%) 16 (17.6%) 4 (33.3%) 0.242
Comorbidities     
 Diabetes 14 (13.6%) 13 (14.3%) 1 (8.3%) 1.000
 Hypertension 37 (35.9%) 36 (39.6%) 1 (8.3%) 0.052
 Heart disease 11 (10.7%) 9 (9.9%) 2 (16.7%) 0.613
Symptoms     
 Fever 73 (70.9%) 63 (69.2%) 10 (83.3%) 0.501
 Cough 70 (68.0%) 63 (69.2%) 7 (58.3%) 0.183
 Dyspnea 24 (23.3%) 16(17.6%) 8 (66.7%) 0.003
 Vomiting 5 (4.9%) 4 (4.4%) 1 (8.3%) 0.34
 Diarrhoea 7 (6.8%) 6 (6.7%) 1 (8.3%) 0.235
Laboratory findings     
 WBC (× 109/L) 5.29 (1.90–25.10); n = 100 5.09 (1.90–25.10); n = 88 7.36 (3.50–18.80); n = 12  < 0.001
 Neutrophil (× 109/L) 3.49 (0.67–22.40); n = 100 3.25 (0.67–22.40); n = 88 6.85 (1.50–17.36); n = 12  < 0.001
 Lymphocyte (× 109/L) 1.06 (0.22–2.89); n = 100 1.15 (0.33–2.89); n = 88 0.64 (0.22–2.40); n = 12 0.012
 NLR 2.93 (0.64–32.23); n = 100 2.64 (0.64–24.76); n = 88 11.7 (2.88–32.32); n = 12  < 0.001
 CRP (mg/L) 2.52 (0.14–280.32); n = 90 1.79 (0.14–177.80); n = 81 80.00 (4.80–280.32); n = 9  < 0.001
 ALT (U/L) 19.17 (4.50–131.20); n = 97 19.17 (4.50–131.20); n = 85 16.50 (6.00–68.30); n = 12 0.634
 AST (U/L) 21.70 (10.00–147.20); n = 84 21.20 (10.00–147.20); n = 72 31.35 (12.00–92.6); n = 12 0.164
  1. WBC white blood cell, NLR leukocyte to lymphocyte ratio, CRP C-reactive protein, ALT alanine transaminase, AST Aspartate transaminase